ArticleJournal of hematology2025
Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program.
Article in Journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emicizumab (Hemlibra) became more accessible for Canadians in 2021, when Canadian Blood Services approved it under formulary for prophylaxis in patients with severe hemophilia A (PWHA) without inhibitors. This offered an alternative to factor VIII (FVIII) prophylaxis. Starting in November 2021, a coordinated effort to offer and support the transition to emicizumab was initiated for all eligible adult PWHA living in British Columbia (BC) and Yukon Territory. Of the 69 PWHA who transitioned to emicizumab, it was observed that some were early adopters whereas others demonstrated more caution and transitioned later. Our aim was to better understand patient and clinical practice factors associated with the early and late transition to emicizumab. Methods: Retrospective data were assessed from clinical records, transition documents and available pre-transition patient-reported surveys for both patient and clinical factors. Results: Of the 83 patients with PWHA eligible for transition, 69 transitioned to emicizumab between November 2021 and December 2023. Median time to emicizumab transition was 10 months. Younger PWHA and those with fewer cumulative comorbidities tended to delay transition to emicizumab. Geographic distance from Vancouver was not significantly associated with transition timing. In multivariable analysis, younger age remained independently associated with longer time to transition (P = 0.0008), while having five or more joints affected by hemophilic arthropathy was associated with later transition (P = 0.007). Conclusions: Using a standardized transition program offered an opportunity to gain a deeper understanding of patient and clinical factors associated with transition to a novel agent. This analysis highlights that certain clinical factors may influence uptake of new therapies within hemophilia care and the importance of early identification of barriers to facilitate treatment uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.